P236 incorporation of ubidecarenone in solid lipid nanoparticles

Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come

“…For these particles, the spherical shape is not induced by the preparative procedure but is a result of the electrostatic interaction between the polar or ionogenic phospholipid head group and the solvent medium and the nature of nonpolar lipid hydrocarbon moieties in the solvent (Bangham et al, 1965;Lasic, 1982). However, it has been shown 718 that it is possible to alter the shape of lipid-based nanoparticles by manipulating the inner compartment of these particles (Miyata and Hotani, 1992;Bunjes et al, 2001;Nickels and Palmer, 2003;Jores et al, 2004;Hasan et al, 2012). In liposomes encapsulating actin polymers, the polymerization of actin led to the deformation of spherical liposomes into dumbbell-and disk-shape particles (Miyata and Hotani, 1992;Nickels and Palmer, 2003).…”

“…For other types of lipid-based nanoparticles, Particle Replication in Non-Wetting Template Technology has been used to produce polymeric core of lipid-polymer hybrid nanoparticles (LPNs) in a needle-like shape that is subsequently coated with phospholipids (Hasan et al, 2012). Furthermore, changes in the lipid type and composition of the lipid mixture during the preparation of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) can lead to platelet-shaped particles (Bunjes et al, 2001;Jores et al, 2004) rather than spherical particles (Saupe et al, 2006;Luo et al, 2011). These alterations in components can further lead to a phase separation between liquid oil and solid lipid in the NLCs, resulting in platelet-shaped particles with an oil droplet on the surface (Bunjes et al, 2001;Jores et al, 2004).…”

Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies

“…Also in this case, the drug was particularly associated with the HSPC portion, and the expulsion of drug due to modified crystallization is unlikely. According to Bunjes and coworkers, 13 the crystallization habits of tripalmitin nanoparticles also vary with the quantity of drug incorporated. The above-described differences may be responsible for the observed higher entrapment efficiencies of ETN and ETP nanoparticles.…”

“…A striking advantage of lipid nanoparticles is the feasibility of large-scale production by a highpressure homogenization technique. 8 Several reports are available on formulation, characterization, 8,9 sterilization, 10 in vitro degradation, and lipid recrystallization behavioral studies by various techniques 11 (eg, differential scanning calorimetry [DSC], 12 small-angle and wide-angle x-ray diffractometry 13 ) and on their in vitro drug release potential. 12 Extensive work by Bunjes and coworkers [14][15][16] reports on crystalline properties of lipids and their recrystallization patterns during nanoparticle preparation, and the influence of nanoparticle size on recrystallization pattern.…”

Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluation

“…5,7 A striking advantage of lipid nanoparticles is the feasibility of large-scale production by a high-pressure homogenization technique. 8 Much research is available on formulation, characterization, 9 in vitro degradation, lipid recrystallization behavioral studies by techniques 10 such as differential scanning calorimetry, 11 small-angle and wide-angle radiograph diffractometry, 12 etc, and their in vitro drug release potential. 11 Extensive research by Bunjes and coworkers [13][14][15] reports on the crystalline properties of lipids and their recrystallization patterns during nanoparticle preparation and the influence of nanoparticle size on the recrystallization pattern.…”